CN Stock MarketDetailed Quotes

688293 Shanghai OPM Biosciences

Watchlist
  • 41.10
  • +0.59+1.46%
Market Closed May 15 15:00 CST
4.67BMarket Cap289.44P/E (TTM)

About Shanghai OPM Biosciences Company

The company was founded in 2013. In 2022, the company landed on the Science and Technology Innovation Board and embarked on a new journey. The company will continue to rely on leading international technology research and development teams and a complete commercial production quality management system, adhere to the quality policy of “perfect craftsmanship, best quality”, and continue to optimize and innovate. The company is a high-tech enterprise specializing in cell culture products and services. The company's main products are cell culture medium series products, customized medium products, and OEM medium. Corporate honors: In January 2025, the company won the “Shanghai Innovative Enterprise Headquarters” issued by the Shanghai Strategic Emerging Industries Leading Group Office. In addition, the company also won the honor of “Chain Leading Enterprise” issued by the Pudong New Area Federation of Industry and Commerce Industry-University-Research Joint Research and Sport Alliance.

Company Profile

Short Name-A奥浦迈生物
Company NameShanghai OPM Biosciences Co., Ltd.
Listing DateSep 2, 2022
Issue Price80.20
Shares Offered20.50M share(s)
FoundedNov 27, 2013
Chairmanzhihua xiao
Legal Representativezhihua xiao
General Managerzhihua xiao
Secretaryxiaohan ma
Employees328
ProvinceShang Hai Shi
Phone021-20780178
Office AddressBuilding 28, Lane 908, Ziping Road, Pudong District, Shanghai
Zip Code201321
Registered AddressNo. 28, Lane 908, Ziping Road, Pudong District, Shanghai
Fax021-68101069
Emailir@opmbiosciences.com
Business License91310115084100518T
BusinessThe company is a high-tech enterprise specializing in cell culture products and services. By organically integrating cell culture products and services, the company provides customers with overall solutions, accelerates the process of new drugs from gene (DNA) to clinical declaration (IND) and marketing application (BLA), and reduces biopharmaceutical production costs by optimizing culture products and processes.

Company Executives

  • Name
  • Position
  • Salary
  • zhihua xiao
  • Chairman, Directors, General Manager, Core Technical Personnel
  • 1.64M
  • liangping ni
  • Directors, Chief Financial Officer
  • 1.40M
  • junjie zhang
  • Directors
  • --
  • yunfen he
  • Directors, Deputy General Manager, Core Technical Personnel
  • 1.73M
  • yuanxing zhang
  • Independent Directors
  • 60.00K
  • xiaomei li
  • Independent Directors
  • 60.00K
  • huaan tao
  • Independent Directors
  • 60.00K
  • hui chen
  • Securities Affairs Representative
  • --
  • qianqian liang
  • Chairman of the Supervisory Board, Auditors, Core Technical Personnel
  • 715.20K
  • jiangfeng li
  • Auditors
  • --
  • chuanyang guo
  • Employee Supervisors
  • 356.70K

Market Insights

Warren Buffett Portfolio Warren Buffett Portfolio

Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.

Unlock Now

Discussing

Berkshire 2025 highlights: Stepping aside as CEO, trade and market volatility
$Berkshire Hathaway-A (BRK.A.US)$ held its highly anticipated annual shareholders meeting Saturday. Here are some key takeaways from the eve Show More